Acute Diverticulitis and C-Reactive Protein as a Prognostic Marker

Acute Diverticulitis Clinical Trial

Official title:

Predictive Value of C-Reactive Protein in Acute Diverticulitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01825967
• Other study ID #: 2013/532
• Status: Not yet recruiting
• Phase: N/A
• First received: March 29, 2013
• Last updated: April 9, 2013
• Start date: April 2013
• Est. completion date: April 2014

Study information

• Verified date: April 2013
• Source: Corporacion Parc Tauli
• Contact: MORA L. LAURA, MD
• Phone: 34639101033
• Email: Lmora[@]tauli.cat
• Is FDA regulated: No
• Health authority: Spain: Ethics Committee
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The management of acute diverticulitis maybe better if we have prognostic markers of evolution.

Hypothesis: C-reactive protein maybe a good prognostic marker of evolution of acute diverticulitis.

The investigators need to know the values of C-reactive protein to predict evolution of acute diverticulitis.

Description:

A prospective observational study. All the patients with TC-diagnosis of acute diverticulitis (AD) had a C-reactive protein (PCR) in the initial blood test.

The investigators will predict evolution of AD with the PCR initial.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Acute Diverticulitis

Exclusion Criteria:

• Other Abdominal Pathologies

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Acute Diverticulitis
• Diverticulitis

Intervention

Other:
• C-reactive protein
measured C-reactive protein in all patients with acute diverticulitis

Locations

Country	Name	City	State
Spain	Corporacion Parc Tauli	Sabadell	Barcelona
Spain	Corporacion parc tauli	Sabadell	Sabadell-Barcelona
Spain	Corporacion Parc Tauli	Sabadell	Sabadell/barcelona
Spain	Corporacion Parc Tauli	Sabadell	Sabadell/barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Corporacion Parc Tauli

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	C-Reactive Protein		24 Hours	Yes